Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy.
Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy.
复制标题
磷脂酰丝氨酸：用于癌症成像与治疗的独特双功能生物标志物
DOI：
10.3390/cancers14102536
复制
发表时间：
2022-05-21
期刊：
影响因子：
5.2
通讯作者：
Qi, Xiaoyang
中科院分区：
文献类型：
--
作者：
Kaynak, Ahmet;Davis, Harold W.;Kogan, Andrei B.;Lee, Jing-Huei;Narmoneva, Daria A.;Qi, Xiaoyang
关键词：
化疗、放疗和手术是癌症的主要治疗方法。即使有这些目前的治疗方式，许多癌症的死亡率仍然很高。因此，仍然迫切需要更安全和更有效的新治疗方法。癌症生物标志物靶向是癌症治疗的一种有前途的策略。癌细胞与正常细胞的区别在于其不受调节的分化和某些生物标志物的过度或不足表达或遗传物质的改变。在这篇综述中，我们讨论了磷脂酰丝氨酸生物标记物靶向治疗和成像方式在临床前和临床研究。我们还评估化疗，放疗和电场增强生物标志物驱动的治疗方法。癌症是全世界的主要死亡原因之一。近年来，已经鉴定出许多癌症相关生物标志物，其用于癌症诊断、预后、筛查和早期检测，以及用于预测和监测致癌作用和治疗效果。磷脂酰丝氨酸（PS）是一种带负电荷的磷脂，主要位于细胞膜的内叶。在许多癌细胞中，PS外化到外细胞膜，这是一个由钙依赖性翻转酶和乱序酶调节的过程。Saposin C与二油酰磷脂酰丝氨酸（SapC-DOPS）纳米囊泡（BXQ-350）和巴维妥昔单抗（Tarvacin，人-小鼠嵌合单克隆抗体）偶联，是正在临床试验中测试用于治疗多种癌症的细胞表面PS靶向药物。此外，在临床前研究中，许多其他PS选择性药物已被用于触发肿瘤相关内皮细胞或癌细胞的细胞毒性。最近的研究表明，通过化疗药物、辐射和外部电场上调表面PS暴露可以用作使癌细胞对PS靶向抗癌药物敏感的新方法。本综述的目的是提供一个独特的双重作用的PS作为一个生物标志物/癌症成像和治疗的目标，并讨论PS为基础的抗癌策略，目前正在积极发展的概述。
Chemotherapy, radiotherapy and surgery are the primary therapies for cancer. Even with these current treatment modalities, the death rate for many cancers is still high. Thus, there is still an urgent need for new therapeutic approaches which are safer and more effective. Cancer biomarker targeting is a promising strategy for cancer treatment. Cancer cells are distinguished from normal cells by their unregulated differentiation and over or under-expression of certain biomarkers or alteration of genetic material. In this review, we discuss phosphatidylserine biomarker-targeted therapy and imaging modalities in pre-clinical and clinical studies. We also appraise chemotherapy, radiotherapy and electric field-enhanced biomarker-driven therapeutic approaches. Cancer is among the leading causes of death worldwide. In recent years, many cancer-associated biomarkers have been identified that are used for cancer diagnosis, prognosis, screening, and early detection, as well as for predicting and monitoring carcinogenesis and therapeutic effectiveness. Phosphatidylserine (PS) is a negatively charged phospholipid which is predominantly located in the inner leaflet of the cell membrane. In many cancer cells, PS externalizes to the outer cell membrane, a process regulated by calcium-dependent flippases and scramblases. Saposin C coupled with dioleoylphosphatidylserine (SapC-DOPS) nanovesicle (BXQ-350) and bavituximab, (Tarvacin, human–mouse chimeric monoclonal antibodies) are cell surface PS-targeting drugs being tested in clinical trial for treating a variety of cancers. Additionally, a number of other PS-selective agents have been used to trigger cytotoxicity in tumor-associated endothelial cells or cancer cells in pre-clinical studies. Recent studies have demonstrated that upregulation of surface PS exposure by chemodrugs, radiation, and external electric fields can be used as a novel approach to sensitize cancer cells to PS-targeting anticancer drugs. The objectives of this review are to provide an overview of a unique dual-role of PS as a biomarker/target for cancer imaging and therapy, and to discuss PS-based anticancer strategies that are currently under active development.
登录
查看更多内容
影响因子：
3.7
作者：
Ungethüm L;Chatrou M;Kusters D;Schurgers L;Reutelingsperger CP
通讯作者：
Reutelingsperger CP
影响因子：
--
作者：
Davis, Harold W;Vallabhapurapu, Subrahmanya D;Qi, Xiaoyang
通讯作者：
Qi, Xiaoyang
影响因子：
3.7
作者：
Chu, Zhengtao;Abu-Baker, Shadi;Qi, Xiaoyang
通讯作者：
Qi, Xiaoyang
影响因子：
--
作者：
Desai, Tanvi J.;Toombs, Jason E.;Udugamasooriya, Damith Gomika
通讯作者：
Udugamasooriya, Damith Gomika
影响因子：
3.7
作者：
Al-Sakere B;André F;Bernat C;Connault E;Opolon P;Davalos RV;Rubinsky B;Mir LM
通讯作者：
Mir LM